Emergent BioSolutions (EBS) Prelim. FY15 adj.-EPS Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Emergent Biosolutions Announces Preliminary 2015 Financial Results, Provides 2016 Financial Outlook, and Outlines New Five-Year (2016-2020) Strategic Growth Plan
January 11, 2016 7:01 AM EST2015 Preliminary Estimates:Total revenues of $520 to $525 million, a 16% increase over 2014 (at midpoint)GAAP net income of $60 to $64 million, a 69% increase over 2014 (at midpoint)Adjusted net income of $73 to $77 million, a 38% increase over 2014 (at midpoint)EBITDA of $130 to $134 million, a 43% increase over 2014 (at midpoint)Year-end cash of approximately $310 million2016 Forecast:Total revenues of $600 to $630 millionGAAP net income of $75 to $85 millionAdjusted net income of $90 to $100 millionEBITDA of $150 to $160 million  2020 Key Financial and... More
